AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

  • End date
    Oct 25, 2027
  • participants needed
  • sponsor
    Eisai Inc.
Updated on 29 August 2022
mini-mental state examination
mental state examination


The primary purpose of this study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial).


Condition Alzheimer's Disease, Alzheimer's Disease, *Healthy Volunteers
Treatment Placebo, BAN2401
Clinical Study IdentifierNCT04468659
SponsorEisai Inc.
Last Modified on29 August 2022


Yes No Not Sure

Inclusion Criteria

Participants must meet all of the following criteria to be included in this
Male or female, age 55 to 80 years inclusive at the time of informed consent
Those 55 to 64 must have 1 of the following additional risk factors, given the
relatively low rates of amyloid positivity less than (<) 65 years
First degree relative diagnosed with dementia onset before age 75, or
Known to possess at least 1 apolipoprotein E4 variant (APOE4) allele, or
Known before screening to have elevated brain amyloid according to previous PET or cerebrospinal fluid (CSF) testing. Individuals with historical amyloid PET scans with intermediate brain amyloid (example, from preclinical Alzheimer's disease (AD) studies such as A4 or EARLY) are eligible to be screened, provided the participant did not participate in any clinical studies involving anti-amyloid therapies subsequent to the PET assessment 2. Global Clinical Dementia Rating (CDR) score of 0 at screening 3. Mini Mental State Examination score greater than or equal to (>=) 27 (with educational adjustments) at screening 4. Wechsler Memory Scale-Revised Logical Memory subscale II (WMS-R LM II) score at screening of >=6 5. A45 Trial: Elevated brain amyloid pathology by amyloid PET: defined as approximately greater than (>) 40 Centiloids on screening scan
A3 Trial: Intermediate levels of brain amyloid pathology by amyloid PET
defined as approximately 20 to 40 Centiloids on screening scan
\. Has a study partner that is willing to participate as a source of
information and has approximately weekly contact with the participant (contact
can be in-person, via telephone or electronic communication). The study
partner must have sufficient contact such that the investigator feels the
study partner can provide meaningful information about the participant's daily
\. Provide written informed consent
\. Willing and able to comply with all aspects of the protocol

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from this
Females who are breastfeeding or pregnant at screening or baseline
Females of childbearing potential who
Within 28 days before study entry, did not use a highly effective method of
For sites outside of the European union (EU), it is permissible that if a
highly effective method of contraception is not appropriate or acceptable to
the participant, then the participant must agree to use a medically acceptable
method of contraception
\. History of transient ischemic attacks (TIA), stroke, or seizures within 12
months of screening
\. Current or history within the past 2 years of psychiatric diagnosis or
symptoms that, in the opinion of the investigator, could interfere with study
\. Contraindications to magnetic resonance imaging (MRI) scanning, including
cardiac pacemaker/defibrillator, ferromagnetic metal implants or exhibit other
significant pathological findings on brain MRI at screening
\. Hypersensitivity to any monoclonal antibody treatment
\. Any immunological disease which is not adequately controlled, or which
requires treatment with immunoglobulins, systemic monoclonal antibodies (or
derivatives of monoclonal antibodies), systemic immunosuppressants, or
plasmapheresis during the study
\. Bleeding disorder that is not under adequate control (including a platelet
count <50,000 or international normalized ratio [INR] >1.5) at screening
\. Results of laboratory tests conducted during screening that are outside
the following
Thyroid stimulating hormone (TSH) above normal range
Abnormally low (below lower limit of normal [LLN]) serum vitamin B12 levels for the testing laboratory (if participant is taking vitamin B12 injections, level should be at or above the LLN for the testing laboratory). A low vitamin B12 is exclusionary, unless the required follow-up labs (homocysteine and methylmalonic acid [MMA]) indicate that it is not physiologically significant 10. Known to be human immunodeficiency virus (HIV) positive 11. Any other clinically significant abnormalities that in the opinion of the investigator require further investigation or treatment or may interfere with study procedures or safety 12. Malignant neoplasms within 3 years of screening (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants with treatment cycles completed at least 6 months before screening). Participants who had malignant neoplasms but who have had at least 3 years of documented uninterrupted remission before screening need not be excluded 13. Answer "yes" to Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before screening, at screening, or at baseline, or has been hospitalized or treated for suicidal behavior in the past 5 years before screening 14. Known or suspected history of drug or alcohol abuse or dependence within 2 years before screening or a positive urine drug test at screening. Participants who test positive for benzodiazepines, opioids, or tetrahydrocannabinol (THC) in urine drug testing need not be excluded unless in the clinical opinion of the investigator this is due to potential drug abuse 15. Taking prohibited medications 16. Participation in a clinical study involving
Any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine within 6 months before screening (anti-amyloid therapies within 1 year before screening), unless it can be documented that the participant was randomized to placebo or never received study drug
Any new chemical entities or investigational drug for AD within 6 months before screening unless it can be documented that the participant received only placebo
Any other investigational medication or device study in the 8 weeks or 5 half-lives (whichever is longer) of the medication before randomization unless it can be documented that the participant was in a placebo treatment arm 17. Planned surgery during the prerandomization phase or within 3 months of randomization, which requires general anesthesia
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note